Lantern Pharma Stock Performance
| LTRN Stock | USD 5.77 0.22 3.67% |
On a scale of 0 to 100, Lantern Pharma holds a performance score of 7. The company secures a Beta (Market Risk) of 1.67, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lantern Pharma will likely underperform. Please check Lantern Pharma's expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Lantern Pharma's current price movements will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Lantern Pharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Lantern Pharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.67) | Five Day Return (12.71) | Year To Date Return 38.37 | Ten Year Return (61.40) | All Time Return (61.40) |
1 | Disposition of 4649 shares by Kreis Leslie W. of Lantern Pharma at 4.4 subject to Rule 16b-3 | 02/27/2024 |
2 | Lantern To Participate in H.C Wainwright Co.s 1st Annual Artificial Intelligence Based Drug Discovery Development Virtual Conference | 03/05/2024 |
3 | Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating Financial Results on March 18th, 2024 at 430 p.m. ET | 03/11/2024 |
4 | Is Lantern Pharma Inc Stock Worth a Buy Wednesday - InvestorsObserver | 03/13/2024 |
5 | Acquisition by Kreis Leslie W. of 35347 shares of Lantern Pharma at 110636.11 subject to Rule 16b-3 | 03/15/2024 |
6 | Lantern Pharma Reports Fourth Quarter Fiscal Year 2023 Financial Results and Business Highlights | 03/18/2024 |
7 | Lantern Pharma Inc. Q4 2023 Earnings Call Transcript | 03/19/2024 |
8 | Analyst Rating Will Lantern Pharma Inc Stock Beat the Market - InvestorsObserver | 03/25/2024 |
9 | Lantern Pharma Trading Down 13.8 percent - MarketBeat | 04/11/2024 |
| Begin Period Cash Flow | 37.7 M |
Lantern |
Lantern Pharma Relative Risk vs. Return Landscape
If you would invest 414.00 in Lantern Pharma on January 20, 2024 and sell it today you would earn a total of 163.00 from holding Lantern Pharma or generate 39.37% return on investment over 90 days. Lantern Pharma is currently generating 0.9868% in daily expected returns and assumes 9.6488% risk (volatility on return distribution) over the 90 days horizon. In different words, 85% of stocks are less volatile than Lantern, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lantern Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lantern Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lantern Pharma, and traders can use it to determine the average amount a Lantern Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1023
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LTRN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.65 actual daily | 85 85% of assets are less volatile |
Expected Return
| 0.99 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Lantern Pharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lantern Pharma by adding it to a well-diversified portfolio.
Lantern Pharma Fundamentals Growth
Lantern Stock prices reflect investors' perceptions of the future prospects and financial health of Lantern Pharma, and Lantern Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lantern Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 23.27 M | ||||
| Shares Outstanding | 10.74 M | ||||
| Price To Book | 1.68 X | ||||
| EBITDA | (17.7 M) | ||||
| Net Income | (15.96 M) | ||||
| Cash And Equivalents | 62.15 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 234.47 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.38 X | ||||
| Book Value Per Share | 3.82 X | ||||
| Cash Flow From Operations | (14.35 M) | ||||
| Earnings Per Share | (1.47) X | ||||
| Market Capitalization | 64.34 M | ||||
| Total Asset | 43.65 M | ||||
| Retained Earnings | (55.24 M) | ||||
| Working Capital | 40.66 M | ||||
About Lantern Pharma Performance
To evaluate Lantern Pharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Lantern Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Lantern Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Lantern Pharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Lantern's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.6 K | -1.7 K | |
| Return On Tangible Assets | (0.37) | (0.38) | |
| Return On Capital Employed | (0.44) | (0.41) | |
| Return On Assets | (0.37) | (0.38) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Lantern Pharma performance evaluation
Checking the ongoing alerts about Lantern Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lantern Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lantern Pharma is way too risky over 90 days horizon | |
| Lantern Pharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (15.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lantern Pharma currently holds about 62.15 M in cash with (14.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Lantern Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Lantern Pharma Trading Down 13.8 percent - MarketBeat |
- Analyzing Lantern Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lantern Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Lantern Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lantern Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lantern Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lantern Pharma's stock. These opinions can provide insight into Lantern Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Lantern Stock analysis
When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.